Search for drugs:
Typing the drug name to query
CANAGLIFLOZIN
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- In a randomized, double-blind, placebo-controlled, active-comparator, 4-way crossover trial, 60 healthy subjects were administered a single oral dose of canagliflozin 300 mg, canagliflozin 1,200 mg (4 times the maximum recommended dose), moxifloxacin, and placebo. No meaningful changes in QTc interval were observed with either the recommended dose of 300 mg or the 1,200 mg dose.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
3
24089
Other ADRs
52841
38328746
Odds Ratio = 0.091
Drug Property Information
ATC Code(s):
- A10BK02 - canagliflozin
- A10BK -
- A10B - "BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"
- A10 - DRUGS USED IN DIABETES
- A - ALIMENTARY TRACT AND METABOLISM
- A10BD16 - canagliflozin
- A10BD - Combinations of oral blood glucose lowering drugs
- A10B - "BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"
- A10 - DRUGS USED IN DIABETES
- A - ALIMENTARY TRACT AND METABOLISM
Active Ingredient:CANAGLIFLOZIN
Active Ingredient UNII:0SAC974Z85
Drugbank ID:DB08907
PubChem Compound:24812758
CTD ID:D000068896
CAS Number:842133-18-0
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
- 200.0 mg/day A10BK02
Chemical Structure: 
SMILE Code:
[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1
[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.